Anemia amongst patients with heart failure - a review
DOI:
https://doi.org/10.12775/JEHS.2024.54.004Keywords
anemia, iron deficiency, heart failure, ferric carboxymaltoseAbstract
Introduction
Anemia and iron deficiency are common comorbidities in population with heart failure. Their association with unfavorable prognostic outcomes and diminished quality of life underscores the imperative need for accurate diagnosis and efficacious treatment interventions. In recent years numerous treatment options have been explored in clinical trials, aimed at addressing the multifaced aspects of these concurrent conditions.
Summary
In patients with heart failure effective treatment of anemia and iron deficiency has demonstrated enhancements in quality of life and exercise capacity. Findings from IRONMAN clinical study have prompted revisions in the latest guidelines from the European Society of Cardiology. The imminent release of results from two ongoing trials holds the potential to reshape the therapeutic landscape for treating individuals with heart failure and iron deficiency. Nevertheless, there is no explicit evidence that studied interventions could improve morbidity or risk of hospitalizations.
References
Pasricha SR, Colman K, Centeno-Tablante E, Garcia-Casal MN, Peña-Rosas JP. Revisiting WHO haemoglobin thresholds to define anaemia in clinical medicine and public health. The Lancet Haematology. 2018 Feb 1;5(2):e60–2.
Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003 Jan 21;107(2):223–5.
Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018 Jul 3;138(1):80–98.
Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000 Jun;35(7):1737–44.
Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. Journal of the American College of Cardiology. 2001 Jun 1;37(7):1775–80.
Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure. Circulation. 2003 Jan 21;107(2):294–9.
Kalra PR, Bolger AP, Francis DP, Genth-Zotz S, Sharma R, Ponikowski PP, et al. Effect of anemia on exercise tolerance in chronic heart failure in men. American Journal of Cardiology. 2003 Apr 1;91(7):888–91.
Kotecha D, Ngo K, Walters JAE, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J. 2011 May;161(5):822-831.e2.
McMurray JJV, Anand IS, Diaz R, Maggioni AP, O’Connor C, Pfeffer MA, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009 Aug;11(8):795–801.
Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine. 2013 Mar 28;368(13):1210–9.
Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. Journal of the American College of Cardiology. 2000 Apr 1;35(5):1245–55.
Camaschella C. New insights into iron deficiency and iron deficiency anemia. Blood Reviews. 2017 Jul 1;31(4):225–33.
Boccio J, Salgueiro J, Lysionek A, Zubillaga M, Weill R, Goldman C, et al. Current knowledge of iron metabolism. Biol Trace Elem Res. 2003 Jun 1;92(3):189–211.
Hurrell RF. Influence of vegetable protein sources on trace element and mineral bioavailability. J Nutr. 2003 Sep;133(9):2973S-7S.
Fontecave M, Pierre JL. Iron: Metabolism, toxicity and therapy. Biochimie. 1993 Jan 1;75(9):767–73.
Andrews NC. Iron Metabolism: Iron Deficiency and Iron Overload. Annual Review of Genomics and Human Genetics. 2000;1(1):75–98.
Waldvogel-Abramowski S, Waeber G, Gassner C, Buser A, Frey BM, Favrat B, et al. Physiology of Iron Metabolism. Transfusion Medicine and Hemotherapy. 2014 May 12;41(3):213–21.
Andrews NC. Disorders of Iron Metabolism. New England Journal of Medicine. 1999 Dec 23;341(26):1986–95.
Ghafourian K, Shapiro JS, Goodman L, Ardehali H. Iron and Heart Failure: Diagnosis, Therapies, and Future Directions. JACC Basic Transl Sci. 2020 Mar;5(3):300–13.
Ganz T. Systemic iron homeostasis. Physiol Rev. 2013 Oct;93(4):1721–41.
Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. The Lancet. 2021 Jan 16;397(10270):233–48.
Hughes DA, Stuart-Smith SE, Bain BJ. How should stainable iron in bone marrow films be assessed? J Clin Pathol. 2004 Oct;57(10):1038–40.
Camaschella C. Iron deficiency. Blood. 2019 Jan 3;133(1):30–9.
Camaschella C. Iron deficiency: new insights into diagnosis and treatment. Hematology. 2015 Dec 5;2015(1):8–13.
Cappellini MD, Musallam KM, Taher AT. Iron deficiency anaemia revisited. Journal of Internal Medicine. 2020;287(2):153–70.
Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010 Aug;31(15):1872–80.
Wu TW, Tsai FP. Comparison of the Therapeutic Effects and Side Effects of Oral Iron Supplements in Iron Deficiency Anemia. Drug Res (Stuttg). 2016 May;66(5):257–61.
Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von Haehling S, et al. Iron status in patients with chronic heart failure. Eur Heart J. 2013 Mar;34(11):827–34.
Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, Albuquerque D de, et al. IRON-HF study: A randomized trial to assess the effects of iron in heart failure patients with anemia. International Journal of Cardiology. 2013 Oct 9;168(4):3439–42.
Shreffler J, Huecker MR. Type I and Type II Errors and Statistical Power. In: StatPearls [Internet] [Internet]. StatPearls Publishing; 2023 [cited 2023 Dec 18]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557530/
Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA. 2017 May 16;317(19):1958–66.
Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency. Journal of the American College of Cardiology. 2007 Oct 23;50(17):1657–65.
Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M, et al. Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency: FERRIC-HF: A Randomized, Controlled, Observer-Blinded Trial. Journal of the American College of Cardiology. 2008 Jan 15;51(2):103–12.
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine. 2009 Dec 17;361(25):2436–48.
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015 Mar 14;36(11):657–68.
van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation. 2017 Oct 10;136(15):1374–83.
Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. 2022 Dec 17;400(10369):2199–209.
Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H. Intravenous iron supplementation therapy. Molecular Aspects of Medicine. 2020 Oct 1;75:100862.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2023 Oct 1;44(37):3627–39.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Dawid Burek, Aleksandra Paszkowska, Aleksandra Kujawa, Urszula Matuszewska, Aleksandra Nykowska, Katarzyna Beutler, Bartosz Bijata
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 366
Number of citations: 0
